A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment (STAR)

Roche

Status: Terminated

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Treatments: Drug: Erlotinib

Study type: Observational

Funder types: Industry

Identifiers

NCT01990261

ML28496

Details and patient eligibility

About

This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults >/= 18 years
• Histologically documented locally advanced, metastatic, or recurrent non-small cell lung carcinoma with wild-type EGFR eligible for Tarceva treatment.
• At least one failed chemotherapy treatment.

Exclusion criteria

• Unknown EGFR mutation status

Trial design

33 participants in 1 patient group

Erlotinib

Description:

Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.

Treatment:

Drug: Erlotinib